Lumos Pharma Announces Abstracts Accepted for Presentation a

18.04.2024 - AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) - Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today ... Seite 1

Related Keywords

Sweden , Stockholm , Andrew Dauber , Peter Clayton , European Congress , International Congress , Growth Hormone Research Society , Similar Annualized Height Velocity , Moderate Pediatric Growth Hormone Deficiency , Promising Investigational Safety Record , Pediatric Growth Hormone Deficiency ,